Vaynrub, A., Mishalani, L., Raikhelkar, J., & Crew, K. D. (2024). Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer. Cardio-Oncology, 10(1). https://doi.org/10.1186/s40959-024-00272-8

Saunders, J., Lee, A., Slinchenkova, K., Chen, Y., Vydyanathan, A., Shaparin, N., & Suda, N. (2024). 7463 Assessing Glycemic Excursions in Patients with Type 2 Diabetes Mellitus Receiving Epidural Steroid Injections. Journal of the Endocrine Society, 8(Supplement_1). https://doi.org/10.1210/jendso/bvae163.671

Katsushima, K., Joshi, K., Yuan, M., Batish, M., Stapleton, S., Jallo, G., Seal, S., Taylor, M. D., Wechsler-Reya, R. J., Eberhart, C. G., & Perera, R. J. (2024). MDB-01. A POSITIVE FEEDBACK LOOP BETWEENLNC-HLX-2-7, HLX, AND MYC STRONGLY PROMOTES GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.450

Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer. (2024). Journal of the College of Physicians and Surgeons Pakistan, 34(06), 682–687. https://doi.org/10.29271/jcpsp.2024.06.682

Bardia, A., Pusztai, L., Albain, K., Ciruelos, E. M., Im, S.-A., Hershman, D., Kalinsky, K., Isaacs, C., Loirat, D., Testa, L., Tokunaga, E., Wu, J., Dry, H., Barlow, W., Kozarski, R., Maxwell, M., Harbeck, N., & Sharma, P. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241248336

Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., D’Silva, D., O’Keefe, K., Kong, R., Maliakal, P., Gao, L., & Schwartz, G. K. (2023). 1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma. Annals of Oncology, 34, S1039. https://doi.org/10.1016/j.annonc.2023.09.1163

Basu, A., Umashankar, S., Musthafa, M., Jones, T., Blevins, K., Brown, T., Heditsian, D., Parker, B., Brain, S., Simmons, C., Hieken, T. J., Ruddy, K., Mainor, C., Tevis, S., Blaes, A., Rugo, H. S., Dunn, I., Melisko, M., Esserman, L., & Hershman, D. L. (2023). 374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial. Annals of Oncology, 34, S332–S333. https://doi.org/10.1016/j.annonc.2023.09.552

Chakraborty, R., Yi, J., Rybicki, L., Preussler, J., Deol, A., Loren, A., Savani, B., Jim, H. S. L., Cerny, J., Reynolds, J., Whitten, J., Wingard, J. R., McGuirk, J. P., Uberti, J., Khera, N., Stiff, P., Jaglowski, S. M., Hashmi, S., Holtan, S. G., … Majhail, N. S. (2023). Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy, 29(6), 388.e1-388.e6. https://doi.org/10.1016/j.jtct.2023.02.011

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A. M., Kalinsky, K., Cortés, J., O’Shaughnessy, J. A., Dieras, V., Carey, L. A., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., … Piccart, M. J. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer, 178, 23–33. https://doi.org/10.1016/j.ejca.2022.10.003

Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Diéras, V., Carey, L. A., Gianni, L., Piccart, M. J., Loibl, S., Goldenberg, D. M., Hong, Q., Olivo, M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00467-1

Naqvi, S. A. A., Fatima, S., Asghar, N., Ijaz, H., Ayaz, A., He, H., Husnain, M., Chakraborty, R., Riaz, I., & Aljama, M. A. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood, 140(Supplement 1), 10111–10113. https://doi.org/10.1182/blood-2022-170869

O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S., Hamilton, E., Loirat, D., Traina, T., Leon-Ferre, R., Hurvitz, S. A., Kalinsky, K., Bardia, A., Henry, S., Mayer, I., Zhu, Y., Phan, S., & Cortés, J. (2022). Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 195(2), 127–139. https://doi.org/10.1007/s10549-022-06602-7